Abstract
We report our eight year experience remission induction therapy in adult patients with acute myeloblastic leukemia. Overall 67 patients were treated, with a mean age of 43.3 years (range 15-75). Two treatment protocols were used. Complete remission (CR) was achieved in 23 patients of 39 receiving protocol A (58%). The 28 last patients were treated with the more aggressive protocol B, and CR was achieved in 23 patients (82%). CR was achieved in 68% of the overall group. The most outstanding predictive factors were age above 30 years, and M-5 morphology as indicating a poor prognosis.
Publication types
-
Comparative Study
-
English Abstract
MeSH terms
-
Adolescent
-
Adult
-
Age Factors
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Cytarabine / administration & dosage
-
Doxorubicin / administration & dosage
-
Female
-
Humans
-
Leukemia, Erythroblastic, Acute / drug therapy
-
Leukemia, Monocytic, Acute / drug therapy
-
Leukemia, Myeloid, Acute / drug therapy*
-
Leukemia, Myeloid, Acute / pathology
-
Leukemia, Myelomonocytic, Acute / drug therapy
-
Leukemia, Promyelocytic, Acute / drug therapy
-
Male
-
Middle Aged
-
Prednisolone / administration & dosage
-
Prognosis
-
Remission Induction*
-
Vincristine / administration & dosage
Substances
-
Cytarabine
-
Vincristine
-
Doxorubicin
-
Prednisolone